Publication

A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen

Related publications (33)

About
Privacy
Disclaimer

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen

Graph Chatbot

Chat with Graph Search

MRI characterization of in vitro clots at 3T and 7T: A technical note

Impact of atrial fibrillation on left atrium haemodynamics: A computational fluid dynamics study

Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs

Tissue Factor-Independent Coagulation Correlates with Clinical Phenotype in Factor XI Deficiency and Replacement Therapy

From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks

Development of cyclic peptide inhibitors of coagulation factor XIa for safer anticoagulation

Atroxlysin-III, A Metalloproteinase from the Venom of the Peruvian Pit Viper Snake Bothrops atrox (Jergon) Induces Glycoprotein VI Shedding and Impairs Platelet Function

Microdevice for Sedimentation-based Separation of Blood Microsamples at the Point of Collection

Peptide macrocycle inhibitor of coagulation factor XII with subnanomolar affinity and high target selectivity

Risk prediction of developing venous thrombosis in combined oral contraceptive users